Jump to content

Moleac

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by John of Reading (talk | contribs) at 12:00, 15 January 2014 (Typo/general fixing, replaced: a 1100 → an 1100 using AWB). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Moleac is a biopharmaceutical company which headquarters are located in Biopolis, a purpose built complex for biomedical sciences research in Singapore.[1] Moleac brings together Asian and Western techniques by identifying medicine discovered in China and developing them into Western mainstream medicine.[2] Moleac's first product, Neuroaid (also written NeuroAiD) is focused on brain stroke recovery and is derived from Traditional Chinese Medicine. It has gained market approval in two countries in 2006 and a clinical trial was started in October 2007 with 1100 patients (CHIMES study).[3]

Products and pipeline

Products

Moleac's first product, Neuroaid stroke treatment, works on the Central Nervous System andI is derived from Traditional Chinese Medicine. It has gained market approval in two countries in 2006 and continues its expansion. Moleac is now present in 10 different courntries, mainly in Asia and Middle-East.[1] A clinical trial was started in October 2007 with 1100 patients (CHIMES).[4]

Pipeline

Moleac's pipeline is to extend NeuroAiD treatment to stroke prevention and to investigate on neurology and aging diseases.[5][2]

Key partnerships

Partnerships have been entered with the following institutions:

  • CHIMES Society: CHIMES Society is an international academic collaboration whose objective is to establish new stroke treatments. CHIMES is a Singaporean non profit society founded by a group of Key Opinion Leaders in stroke, South-East Asia regional experts and clinicians interested in implementing a research project on Traditional Chinese Medicine Efficacy on Stroke recovery. In October 2007, CHIMES Society initiated an 1100 patient clinical trial aimed at measuring the efficacy of NeuroAid in reducing neurological deficit and improving functional outcome in patients with cerebral infarction. This trial is currently enrolling and details are available at the NHI www.ClinicalTrial.gov [3].
  • First Teaching Hospital of Tianjin University of Traditional Chinese Medicine (Tianjin Medical University): First Teaching Hospital of Tianjin University of TCM is the largest TCM hospital of China. It was first established in 1954.[4]

Awards

Frost & Sullivan Excellence in Healthcare Awards

Moleac received two awards for its Neuroaid stroke treatment. In 2009, Moleac was named Singapore Entrepreneurial Company of the Year at the Frost & Sullivan Excellence in Healthcare Awards. Frost & Sullivan granted this award to Moleac te recognise its ability to be a major player in "various healthcare segments" and to acknowledge the good practices displayed.[5]

Biospectrum Asia Pacific Award

In 2010, Moleac was elected Asia emerging company of the year by Biospectrum. This award was granted by Biospectrum for two main reasons: first its initiative to bridge a therapeutic gap in stroke recovery, second, for the rapid and efficient commercialisation of Neuroaid stroke treatment.[6]

References

  1. ^ Asiabiotech/industry watch - APBN-vol 10-No 1, June 2006
  2. ^ ePanorama,From Pins to Pills, 2006-03-31, https://www.bcg.com/alumni/ePanorama/article.jsp?pubID=1568&PubRef=Mar/Apr
  3. ^ Medical Tribune, November 2009, NeuroAiD: Expanding the frontiers of neurological rehabilitation
  4. ^ 9.2006/12/11, Reuters, Moleac turns a TCM into stroke Treatment
  5. ^ Heurteaux, C., et al., Neuroprotective and neuroproliferative activities of NeuroAiD (MLC601, MLC901), a Chinese..., Neuropharmacology (2010), doi:10.1016/j.neuropharm.2010.01.001
Retrieved from "https://en.wikipedia.org/w/index.php?title=Moleac&oldid=590804521"